Read the original:
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
Related Post
- Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of... - January 25th, 2025
- PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider - January 25th, 2025
- America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search - January 25th, 2025
- LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) - January 25th, 2025
- Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual... - January 25th, 2025
- Vincerx Pharma, Inc. Announces Reverse Stock Split - January 25th, 2025
- Impact BioMedical Inc. to Present at The Microcap Conference - January 25th, 2025
- Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - January 25th, 2025
- Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference - January 25th, 2025
- Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity - January 25th, 2025
- X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - January 25th, 2025
- Appendix 4C – Q2 FY25 Quarterly Cash Flow Report - January 25th, 2025
- Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care - January 25th, 2025
- Gelteq Appoints Matthew Jones as Head of Sports Performance - January 25th, 2025
- Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia - January 25th, 2025
- AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET - January 25th, 2025
- Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in... - January 25th, 2025
- Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated... - January 25th, 2025
- Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure - January 25th, 2025
- Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - January 23rd, 2025
- Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement - January 23rd, 2025
- Spectral AI Provides Update to Investors - January 23rd, 2025
- Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ - January 23rd, 2025
- Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer - January 23rd, 2025
- Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - January 23rd, 2025
- AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - January 23rd, 2025
- Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - January 23rd, 2025
- NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental... - January 23rd, 2025
- Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies - January 23rd, 2025
- Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development - January 23rd, 2025
- Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - January 23rd, 2025
- Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - January 23rd, 2025
- Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit... - January 23rd, 2025
- AB Science will participate in the Biomed Forum investors conference - January 23rd, 2025
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - January 23rd, 2025
- Nusano to Present at Piper Sandler Next-Gen RadioPharma Symposium - January 23rd, 2025
- Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 - January 23rd, 2025
- Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand - January 23rd, 2025
- Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab - January 23rd, 2025
- CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities - January 21st, 2025
- Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - January 21st, 2025
- Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments - January 21st, 2025
- ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor - January 21st, 2025
- ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - January 21st, 2025
- Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and Ampersand - January 21st, 2025
- Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - January 21st, 2025
- Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - January 21st, 2025
- Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - January 21st, 2025
- Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - January 21st, 2025
- Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing - January 21st, 2025
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 21st, 2025
- Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network - January 21st, 2025
- Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology - January 21st, 2025
- Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta - January 21st, 2025
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 21st, 2025
- Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 21st, 2025
- Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 21st, 2025
- Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 21st, 2025
- Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 21st, 2025
- Serina Therapeutics Announces Sale of UniverXome Subsidiary - January 19th, 2025
- Radiance has been selected to Present at the 2025 Biotech Showcase™ Alongside the J.P. Morgan Healthcare Conference - January 19th, 2025
- Biologic Pharmamedical Launches Innovative Functional Beverages for Health, Longevity, and Performance - January 19th, 2025
- Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders - January 19th, 2025
- Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia - January 19th, 2025
- Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle... - January 19th, 2025
- Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - January 19th, 2025
- Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - January 19th, 2025
- Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence - January 19th, 2025
- Scorpius Holdings Cancels Planned Reverse Stock Split - January 19th, 2025
- Cannabis Means Business (CMB), New York Global Edition, Opens Registration - January 19th, 2025
- XORTX Announces Change of Auditor - January 19th, 2025
- Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) - January 19th, 2025
- Lifecore Biomedical Announces Special Stockholder Meeting - January 19th, 2025
- Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines - January 17th, 2025
- Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - January 17th, 2025
- Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland... - January 17th, 2025
- Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma - January 17th, 2025
- Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - January 17th, 2025
- Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis - January 17th, 2025
- Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development - January 17th, 2025
Recent Comments